Hepatitis C: An emerging epidemic

Clinics in Family Practice

Volumn 6, Issue 3, 2004, Pages 589-605

  Shehab, Thomas M ^a  

^a St Joseph Mercy Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEOSIDE DERIVATIVE; PEGINTERFERON; RIBAVIRIN;

ALCOHOL CONSUMPTION; ARTICLE; CHILDHOOD DISEASE; CLINICAL FEATURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; ECONOMIC ASPECT; HEPATITIS C; HUMAN; INFECTION RISK; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; MEDICAL SPECIALIST; PATIENT EDUCATION; PATIENT REFERRAL; PREVALENCE; PRIMARY MEDICAL CARE; RISK FACTOR; SYMPTOMATOLOGY; TREATMENT INDICATION; VIRUS LOAD;

EID: 4344561708     PISSN: 15225720     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cfp.2004.03.006     Document Type: Review

References (87)

1. National Institutes of Health Consensus Development Conference Management of hepatitis C Hepatology 26 Suppl 1997 1S-156S
2. Alter M.J. Kruszon-Moran D. Nainan O.V. McQuillan G.M. Gao F. Moyer L.A. et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 N Engl J Med 341 1999 556-562
3. Di Bisceglie A.M. Goodman Z.D. Ishak K.G. Hoofnagle J.H. Melpolder J.J. Alter H.J. Long-term clinical and histopathological follow-up of chronic post-transfusion hepatitis Hepatology 14 1991 969-974
4. Tremolada F. Cassin C. Alberti A. Drago C. Tagger A. Ribero M.L. et al. Long-term follow-up of NANB (type C) post-transfusion hepatitis J Hepatol 16 1992 273-281
5. Seeff L.B. Buskell-Bales Z. Wright E.C. Durako S.J. Alter H.J. Iber F.L. et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis N Engl J Med 327 1992 1906-1911
6. Choo Q.L. Kuo G. Weiner A.J. Overby L.R. Bradley D.W. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome Science 244 1989 359-362
7. Kuo G. Choo G.L. Alter H.J. Gitnick G.L. Redeker A.G. Purcell R.H. et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis Science 244 1989 362-364
8. Alter H.J. New kit on the block: evaluation of second-generation assays for detection of antibody to the hepatitis C virus Hepatology 15 1992 350
9. Seeff L.B. Hoofnagle J.H. National Institutes of Health Consesus Development Conference: management of hepatitis C Hepatology 36 Suppl 2002 S1-S2
10. Center for Disease Control and Prevention Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease MMWR Recomm Rep 47 1998 1-39
11. Alter M.J. Prevention of spread of hepatitis C Hepatology 36 Suppl 2002 S93-S98
12. Velati C. Romano L. Baruffi L. Pappalettera M. Carreri V. Zanetti A.R. Residual risk of transfusion-transmitted HCV and HIV infections by antibody-screened blood in Italy Transfusion 42 2002 989-993
13. Gresens C.J. Holland P.V. The disappearance of transfusion-transmitted hepatitis C virus infections in the United States Clin Liver Dis 5 2001 1105-1113
14. Jonas M.M. Children with hepatitis C Hepatology 36 Suppl 2002 S173-S178
15. Roberts E.A. Yeung L. Maternal-infant transmission of hepatitis C virus infection Hepatology 36 Suppl 2002 S106-S111
16. Terrault N.A. Sexual activity as a risk factors for hepatitis C Hepatology 36 Suppl 2002 S99-S105
17. Halfon P. Riflet H. Renou C. Quentin Y. Cacoub P. Molecular evidence of male-to-female sexual transmission of hepatitis C virus after vaginal and anal intercourse J Clin Microbiol 39 2001 1204-1206
18. Thomas D. Zenilman J. Alter H. Shih J. Galai N. Carella A. et al. Sexual transmission of hepatitis C virus among patients attending sexually transmitted diseases clinics in Baltimore: an analysis of 309 sex partnerships J Infect Dis 171 1995 768-775
19. Bresters D. Mauser-Bunschoten E.P. Reesink H.W. Roosendaal G. van der Poel C.L. Chamuleau R.A. et al. Sexual transmission of hepatitis C virus Lancet 342 1993 210-211
20. Meisel H. Reip A. Faltus B. Lu M. Porst H. Wiese M. et al. Transmission of hepatitis C virus to children and husbands by women infected with contaminated anti-D immunoglobulin Lancet 345 1995 1209-1211
21. Shehab T.M. Sonnad S. Jeffries M. Gunaratnum N. Lok A.S.F. Current practice patterns of primary care physicians in the management of patients with hepatitis C Hepatology 30 1999 794-800
22. Coppola A.G. Sharma V.K. Raufman J-P. A survey of primary care residents opinions and practices related to hepatitis C (HCV). Presented at Digestive Disease Week. San Diego, May 21-24, 2000.
23. Nicklin D.E. Schultz C. Brensinger C.M. Wilson J.P. Current care of hepatitis C-positive patients by primary care physicians in an integrated delivery system J Am Board Fam Pract 12 1999 427-435
24. Shehab T.M. Sonnad S.S. Lok A.S. Management of hepatitis C patients by primary care physicians in the USA: results of a national survey J Viral Hepat 8 2001 377-383
25. Shehab T.M. Sonnad S. Gebremariam A. Schoenfeld P. Knowledge of hepatitis C screening and management by internal medicine residents: trends over 2 years Am J Gastroenterol 97 2002 1216-1222
26. Shehab T.M. Orrego M. Chunduri R. Lok A.S. Identification and management of hepatitis C patients in primary care clinics Am J Gastroenterol 98 2003 639-644
27. Kim W.R. The burden of hepatitis C in the United States Hepatology 36 Suppl 2002 S30-S34
28. Kim W. Gross J. Poterucha J. Locke G. Dickson E. Outcome of hospital care of liver disease associated with hepatitis C in the United States Hepatology 33 2001 201-206
29. Pawlotsky J.M. Use and interpretation of virological tests for hepatitis C Hepatology 36 Suppl 2002 S65-S73
30. Pawlotsky J.M. Bastie A. Pellet C. Remire J. Darthuy F. Wolfe L. et al. Significance of indeterminate third-generation hepatitis C virus recombinant immunoblot assay J Clin Microbiol 34 1996 80-83
31. Colin C. Lanoir D. Touzet S. Meyaud-Kraemer L. Bailly F. Trepo C. HEPATITIS Group. Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature J Viral Hepat 8 2001 87-95
32. Pawlotsky J.M. Prescott L. Simmonds P. Pellet C. Laurent-Puig P. Labonne C. et al. Serological determination of hepatitis C virus genotype: comparison with a standardized genotyping assay J Clin Microbiol 35 1997 1734-1739
33. Sandres K. Dubois M. Pasquier C. Puel J. Izopet J. Determination of HCV genotype using two antibody assays and genome typing Eur J Clin Microbiol Infect Dis 20 2001 666-669
34. Seeff L.B. Natural history of chronic hepatitis C Hepatology 36 Suppl 2002 S35-S46
35. Seeff L.B. Why is there such difficulty in defining the natural history of hepatitis C? Transfusion 40 2000 1161-1164
36. Alter M.J. Margolis H.S. Krawczynski K. Judson F.N. Mares A. Alexander W.J. et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team N Engl J Med 327 1992 1899-1905
37. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group N Engl J Med 340 1999 1228-1233
38. Tong M.J. el-Farra N.S. Reikes A.R. Co R.L. Clinical outcomes after transfusion-associated hepatitis C N Engl J Med 332 1995 1463-1466
39. Locasciulli A. Testa M. Pontisso P. Benvegnu L. Fraschini D. Corbetta A. et al. Prevalence and natural history of hepatitis C infection in patients cured of childhood leukemia Blood 90 1997 4628-4633
40. Wiese M. Berr F. Lafrenz M. Porst H. Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study Hepatology 32 2000 91-96
41. Vogt M. Lang T. Frosner G. Klingler C. Sendl A.F. Zeller A. et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening N Engl J Med 341 1999 866-870
42. Gordon S.C. Bayati N. Silverman A.L. Clinical outcome of hepatitis C as a function of mode of transmission Hepatology 28 1998 562-567
43. Thomas D.L. Astemborski J. Rai R.M. Anania F.A. Schaeffer M. Galai N. et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors JAMA 284 2000 450-456
44. Hoofnagle J.H. Course and outcome of hepatitis C Hepatology 36 Suppl 2002 S21-S29
45. Montalto G. Zignego A.L. Ruggeri M.I. Giannini C. Soresi M. Monti M. et al. Serum HCV-RNA and liver histologic findings in patients with long-term normal transaminases Dig Dis Sci 42 1997 1703-1707
46. Healey C.J. Chapman R.W. Fleming K.A. Liver histology in hepatitis C infection: a comparison between patients with persistently normal or abnormal transaminases Gut 37 1995 274-278
47. Dienstag J.L. The role of liver biopsy in chronic hepatitis C Hepatology 36 Suppl 2002 S152-S160
48. Marcellin P. Asselah T. Boyer N. Fibrosis and disease progression in hepatitis C Hepatology 36 Suppl 2002 S47-S56
49. Fontana R.J. Lok A.S. Noninvasive monitoring of patients with chronic hepatitis C Hepatology 36 Suppl 2002 S57-S64
50. Fattovich G. Giustina G. Degos F. Tremolada F. Diodata G. Almasio P. et al. Morbidity and mortality in compensated cirrhosis Type C: a retrospective follow-up study of 384 patients Gastroenterology 112 1997 463-472
51. Niederau C. Lange S. Heintges T. Erhardt A. Buschkamp M. Hurter D. et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study Hepatology 28 1998 1687-1695
52. El-Serag H.B. Hepatocellular carcinoma and hepatitis C in the United States Hepatology 36 Suppl 2002 S74-S83
53. Arguedas M.R. Chen V.K. Eloubeidi M.A. Fallon M.B. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis Am J Gastroenterol 98 2003 679-690
54. Gebo K.A. Chander G. Jenckes M.W. Ghanem K.G. Herlong H.F. Torbenson M.S. et al. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review Hepatology 36 Suppl 2002 S84-S92
55. El-Serag H.B. Hepatocellular carcinoma and hepatitis C in the United States Hepatology 36 Suppl 2002 S74-S83
56. Arguedas M.R. Chen V.K. Eloubeidi M.A. Fallon M.B. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis Am J Gastroenterol 98 2003 679-690
57. Gebo K.A. Chander G. Jenckes M.W. Ghanem K.G. Herlong H.F. Torbenson M.S. et al. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review Hepatology 36 Suppl 1 2002 S84-S92
58. Araya V. Rakela J. Wright T. Hepatitis C after orthotopic liver transplantation Gastroenterology 112 1997 575-582
59. Dickson R.C. Caldwell S.H. Ishitani M.B. Lau J.Y. Driscoll C.J. Stevenson W.C. et al. Clinical and histologic patterns of early graft failure due to recurrent hepatitis C in four patients after liver transplantation Transplantation 61 1996 701-705
60. Everhart J.E. Weig Y. Eng H. Charlton M.R. Persing D.H. Wiesner R.H. et al. Recurrent and new hepatitis C virus infection after liver transplantation Hepatology 29 1999 1220-1226
61. Cacoub P. Renou C. Rosenthal E. Cohen P. Loury I. Loustaud-Ratti V. et al. Extrahepatic manifestations associated with hepatitis C virus infection: a prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C Medicine 79 2000 47-56
62. El-Serag H.B. Hampel H. Yeh C. Rabeneck L. Extrahepatic manifestations of hepatitis C among United States male veterans Hepatology 36 2002 1439-1445
63. Misiani R. Bellavita P. Fenili D. Vicari O. Marchesi D. Sironi P.L. et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus N Engl J Med 330 1994 751-756
64. Casato M. Agnello V. Pucillo L.P. Knight G.B. Leoni M. Del Vecchio S. et al. Predictors of long term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection Blood 90 1997 3865-3873
65. Regev A. Jeffers L.J. Hepatitis C and alcohol Alcohol Clin Exp Res 23 1999 1543-1551
66. Coelho-Little M.E. Jeffers L.J. Bernstein D.E. Goodman J.J. Reddy K.R. de Medina M. et al. Hepatitis C virus in alcoholic patients with and without clinically apparent liver disease Alcohol Clin Exp Res 19 1995 1173-1176
67. Roudot-Thoraval F. Bastie A. Pawlotsky J.M. Dhumeaux D. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients Hepatology 26 1997 485-490
68. Ostapowicz G. Watson K.J. Locarnini S.A. Desmond P.V. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection Hepatology 27 1998 1730-1735
69. Peters M.G. Terrault N.A. Alcohol use and hepatitis C Hepatology 36 Suppl 2002 220-225
70. Arguedas M.R. Heudebert G.R. Fallon M.B. Stinnett A.A. The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C viral infection in the United States Am J Gastroenterol 97 2002 721-728
71. Margolis H.S. Hepatitis update: the role of primary care practitioners in prevention, treatment, and vaccination Ethn Dis 12 2002 S33-S35
72. Jacobs R.J. Koff R.S. Meyerhoff A.S. The cost-effectiveness of vaccinating chronic hepatitis C patients against hepatitis A Am J Gastroenterol 97 2002 427-434
73. Bolyard E.A. Tablan O.C. Williams W.W. Pearson M.L. Shapiro C.N. Deitchmann S.D. Guideline for infection control in healthcare personnel 1998 Infect Control Hosp Epidemiol 19 1998 407-463
74. Lindsey K.L. Introduction to the therapy of hepatitis C Hepatology 36 Suppl 2002 S114-S120
75. DiBisceglie A.M. Hoofnagle J.H. Optimal therapy of hepatitis C Hepatology 36 Suppl 2002 S121-S132
76. Camma C. Giunta M. Pinzello G. Morabito A. Verderio P. Pagliaro L. Chronic hepatitis C and interferon alpha: conventional and cumulative meta-analyses of randomized controlled trials Am J Gastroenterol 94 1999 581-595
77. Lindsay K.L. Therapy of hepatitis C: overview Hepatology 26 Suppl 1 1997 71S
78. Poynard T. Marcellin P. Lee S.S. Niederau C. Minuk G.S. Ideo G. et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group Lancet 352 1998 1426-1432
79. McHutchison J.G. Gordon S.C. Schiff E.R. Shiffman M.L. Lee W.M. Rustgi V.K. et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group N Engl J Med 339 1998 1485-1492
80. McHutchison J.G. Manns M. Patel K. Poynard T. Lindsay K.L. Trepo C. et al. International Hepatitis Interventional Therapy Group Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C Gastroenterology 123 2002 1061-1069
81. Manns M.P. McHutchison J.G. Gordon S.C. Rustgi V.K. Shiffman M. Reindollar R. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958-965
82. Fried M.W. Shiffman M.L. Reddy K.R. Smith C. Marinos G. Goncales F.L. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975-982
83. Hoofnagle J.H. Therapy for acute hepatitis C N Engl J Med 345 2001 1495-1497
84. Gerlach J.T. Diepolder H.M. Zachoval R. Gruener N.H. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance Gastroenterology 125 2003 80-88
85. Jaeckel E. Cornberg M. Wedemeyer H. Santantonio T. Mayer J. Zankel M. et al. Treatment of acute hepatitis C with interferon alfa-2b N Engl J Med 345 2001 1452-1457
86. Kage M. Fujisawa T. Shiraki K. Tanaka T. Fujisawa T. Kimura A. et al. Pathology of chronic hepatitis C in children. Child Liver Study Group of Japan Hepatology 26 1997 771-775
87. Jonas M.M. Treatment of chronic hepatitis C in pediatric patients Clin Liver Dis 4 1999 855-867